Understand the source comparison
Best Peptides for IBD: Therapeutic Comparison
Before selecting peptides for IBD research protocols, understanding their distinct mechanisms, administration routes, and evidence quality clarifies which compound fits specific research goals. BPC-157 VEGF upregulation, FAK phosphorylation, epithelial migrati
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting peptides for IBD research protocols, understanding their distinct mechanisms, administration routes, and evidence quality clarifies which compound fits specific research goals.
- BPC-157
- VEGF upregulation, FAK phosphorylation, epithelial migration
- Subcutaneous or intraperitoneal injection
- Extensive preclinical (15+ IBD model studies), no Phase III human trials
- 10 mcg/kg daily for 7–14 days
- Fastest mucosal healing timelines in colitis models. 60–70% ulcer area reduction at 7 days
- KPV
- NF-κB nuclear translocation inhibitor, localized anti-inflammatory
- Oral (targets colonic tissue directly)
- Phase II human trial completed (UC patients), multiple preclinical studies
- 10mg oral three times daily for 8 weeks (human equivalent dose)
- Only peptide with oral bioavailability sufficient for colonic delivery. No systemic immunosuppression
- Thymosin Beta-4
- T-cell differentiation toward Tregs, anti-fibrotic collagen remodeling
- Subcutaneous injection
- Phase I safety established, Phase II IBD trials pending
- 2.5mg twice weekly for 4–12 weeks
- Dual immune modulation and anti-fibrotic action. Reduces stricture risk in chronic inflammation